← Back to Search

Iron Supplement

Iron Supplements for Iron-Deficiency Anemia

N/A
Waitlist Available
Research Sponsored by Dr. Anil K. Gupta Medicine Professional Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks from baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to compare different types of iron supplements to see which ones are more effective and better tolerated for treating iron deficiency anemia. The study will focus on the cost and tolerability of the supplements

Who is the study for?
This trial is for adults aged 18 or older who are dealing with iron deficiency anemia. Participants should have a confirmed diagnosis of IDA and be willing to take oral iron supplements. Specific details about what might exclude someone from participating aren't provided, but typically these criteria would involve health conditions that could interfere with the study or risk participant safety.
What is being tested?
The trial is testing three different types of iron supplements: Ferrous Ascorbate (EBMfer), Ferrous Fumarate (Eurofer), and Polysaccharide Iron (FeraMax). It aims to find out which one raises hemoglobin levels best over a period of three months, considering both effectiveness and tolerability.
What are the potential side effects?
Common side effects of oral iron supplements can include stomach upset, constipation, diarrhea, nausea, and dark stools. The severity can vary among individuals and different formulations may reduce some side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks from baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks from baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Hemoglobin Levels
Secondary study objectives
Change in Serum Ferritin
Tolerability of Study Medication - Discontinuation Rate

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Active Control
Group I: FeraMAXActive Control1 Intervention
Polysaccharide Iron - 150mg
Group II: EuroferActive Control1 Intervention
Ferrous Fumarate - 300 mg
Group III: EBMferActive Control1 Intervention
Ferrous Ascorbate - 100 mg

Find a Location

Who is running the clinical trial?

Dr. Anil K. Gupta Medicine Professional CorporationLead Sponsor
~20 spots leftby Feb 2025